Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$17.09
At close: May 27 EDT
$17.09
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
Neurogene Analyst Ratings and Price Targets | NASDAQ:NGNE | Benzinga
Neurogene Inc has a consensus price target of $39.83 based on the ratings of 7 analysts. The high is $72 issued by Leerink Partners on November 12, 2024. The low is $16 issued by BMO Capital on April 14, 2025. The 3 most-recent analyst ratings were released by BMO Capital, Baird, and HC Wainwright & Co. on May 20, 2025, May 16, 2025, and May 13, 2025, respectively. With an average price target of $30.33 between BMO Capital, Baird, and HC Wainwright & Co., there's an implied 77.49% upside for Neurogene Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
Baird
HC Wainwright & Co.
BMO Capital
Stifel
1calculated from analyst ratings
Analyst Ratings for Neurogene
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/20/2025 | Buy Now | 28.73% | BMO Capital | Evan David Seigerman45% | $16 → $22 | Maintains | Outperform | Get Alert |
| 05/16/2025 | Buy Now | 40.43% | Baird | Joel Beatty67% | $38 → $24 | Downgrade | Outperform → Neutral | Get Alert |
| 05/13/2025 | Buy Now | 163.31% | HC Wainwright & Co. | Mitchell Kapoor44% | $50 → $45 | Maintains | Buy | Get Alert |
| 04/14/2025 | Buy Now | -6.38% | BMO Capital | Keith Tapper52% | $45 → $16 | Maintains | Outperform | Get Alert |
| 03/25/2025 | Buy Now | 192.57% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $50 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 221.83% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2024 | Buy Now | 163.31% | BMO Capital | Keith Tapper52% | $60 → $45 | Maintains | Outperform | Get Alert |
| 11/19/2024 | Buy Now | 221.83% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 11/12/2024 | Buy Now | 251.08% | Stifel | Paul Matteis43% | $44 → $60 | Maintains | Buy | Get Alert |
| 11/12/2024 | Buy Now | 251.08% | BMO Capital | Keith Tapper52% | $65 → $60 | Maintains | Outperform | Get Alert |
| 11/12/2024 | Buy Now | 321.3% | Leerink Partners | Mani Foroohar47% | $45 → $72 | Maintains | Outperform | Get Alert |
| 11/12/2024 | Buy Now | 321.3% | Baird | Joel Beatty67% | $54 → $72 | Maintains | Outperform | Get Alert |
| 11/12/2024 | Buy Now | 221.83% | HC Wainwright & Co. | Mitchell Kapoor44% | $49 → $55 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 186.72% | HC Wainwright & Co. | Mitchell Kapoor44% | $51 → $49 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 280.34% | BMO Capital | Keith Tapper52% | → $65 | Initiates | → Outperform | Get Alert |
| 06/20/2024 | Buy Now | 198.42% | HC Wainwright & Co. | Mitchell Kapoor44% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 06/11/2024 | Buy Now | 215.97% | Baird | Joel Beatty67% | → $54 | Initiates | → Outperform | Get Alert |
| 06/04/2024 | Buy Now | 198.42% | HC Wainwright & Co. | Mitchell Kapoor44% | $51 → $51 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 198.42% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $51 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 221.83% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 221.83% | HC Wainwright & Co. | Mitchell Kapoor44% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 04/29/2024 | Buy Now | 169.16% | Leerink Partners | Mani Foroohar47% | → $46 | Initiates | → Outperform | Get Alert |
| 03/21/2024 | Buy Now | — | William Blair | Sami Corwin11% | — | Initiates | → Outperform | Get Alert |
| 03/19/2024 | Buy Now | 221.83% | HC Wainwright & Co. | Mitchell Kapoor44% | $45 → $55 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | 163.31% | HC Wainwright & Co. | Mitchell Kapoor44% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 01/17/2024 | Buy Now | 163.31% | HC Wainwright & Co. | Mitchell Kapoor44% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2024 | Buy Now | 163.31% | HC Wainwright & Co. | Mitchell Kapoor44% | → $45 | Initiates | → Buy | Get Alert |
| 01/05/2024 | Buy Now | 81.39% | Stifel | Paul Matteis43% | → $31 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Neurogene (NGNE) stock?
The latest price target for Neurogene (NASDAQ:NGNE) was reported by BMO Capital on May 20, 2025. The analyst firm set a price target for $22.00 expecting NGNE to rise to within 12 months (a possible 28.73% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Neurogene (NGNE)?
The latest analyst rating for Neurogene (NASDAQ:NGNE) was provided by BMO Capital, and Neurogene maintained their outperform rating.
When was the last upgrade for Neurogene (NGNE)?
There is no last upgrade for Neurogene
When was the last downgrade for Neurogene (NGNE)?
The last downgrade for Neurogene Inc happened on May 16, 2025 when Baird changed their price target from $38 to $24 for Neurogene Inc.
When is the next analyst rating going to be posted or updated for Neurogene (NGNE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurogene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurogene was filed on May 20, 2025 so you should expect the next rating to be made available sometime around May 20, 2026.
Is the Analyst Rating Neurogene (NGNE) correct?
While ratings are subjective and will change, the latest Neurogene (NGNE) rating was a maintained with a price target of $16.00 to $22.00. The current price Neurogene (NGNE) is trading at is $17.09, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
